Fraunhofer Center for Molecular Biotechnology (FhCMB) has received a contract from the US National Institute of Allergy and Infectious Diseases to develop vaccine technologies for advancing the next generation of anthrax vaccines.
National Institute of Allergy and Infectious Diseases is part of the National Institutes of Health (NIH).
As part of the contract, Fraunhofer will receive $1.76m for the first year of nearly $ 9.9m total funding depending on contract options made.
The contract will support candidate vaccine components and technologies development, which accelerates the immune response for use following intentional release of Bacillus anthracis or in response to naturally occurring outbreaks.
Fraunhofer, using its interdisciplinary services, will complete works associated with the contract, which includes biomass generation, agro infiltration and protein purification, formulation development and stability, pre-clinical activities, pre-IND activities, IND submission as well as the option to conduct a phase 1 clinical trial.
The first phase of the contract will run through 2013.
The company will partner with Isconova AB, a Swedish research and development company during the clinical trial and with iBio Inc, its commercialization partner on completion of the clinical trials of the Anthrax vaccine.
